[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 642,996
  • Shares Outstanding, K 30,330
  • Annual Sales, $ 344,230 K
  • Annual Income, $ -24,160 K
  • EBIT $ -25 M
  • EBITDA $ 12 M
  • 60-Month Beta 1.04
  • Price/Sales 1.86
  • Price/Cash Flow 18.97
  • Price/Book 1.39

Options Overview Details

View History
  • Implied Volatility 82.15% (+17.63%)
  • Historical Volatility 52.60%
  • IV Percentile 85%
  • IV Rank 66.31%
  • IV High 101.74% on 02/20/26
  • IV Low 43.60% on 08/19/25
  • Expected Move (DTE 24) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 349
  • Open Int (30-Day) 399
  • Expected Range 21.38 to 21.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.38
  • Number of Estimates 1
  • High Estimate $-0.38
  • Low Estimate $-0.38
  • Prior Year $0.15
  • Growth Rate Est. (year over year) -353.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.51 +9.58%
on 06/02/26
22.18 -3.61%
on 05/28/26
+1.23 (+6.10%)
since 05/22/26
3-Month
17.72 +20.64%
on 05/14/26
26.68 -19.87%
on 04/08/26
-4.37 (-16.97%)
since 03/23/26
52-Week
14.59 +46.54%
on 08/04/25
44.28 -51.72%
on 01/26/26
+2.53 (+13.42%)
since 06/23/25

Most Recent Stories

More News
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal

Stokes was one of 22 financial leaders recognized in the Greater Houston area

CSTL : 21.38 (+0.85%)
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FRIENDSWOOD, Texas , June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June...

CSTL : 21.38 (+0.85%)
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus

FRIENDSWOOD, Texas , June 16, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...

CSTL : 21.38 (+0.85%)
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

FRIENDSWOOD, Texas , May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...

CSTL : 21.38 (+0.85%)
Castle Biosciences' AdvanceAD-Txâ„¢ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutions

CSTL : 21.38 (+0.85%)
Castle Biosciences Reports First Quarter 2026 Results

Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased...

CSTL : 21.38 (+0.85%)
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

Longstanding   collaborations with   AIM at Melanoma, the Melanoma Research Foundation,   The   Skin Cancer Foundation, IMPACT Melanoma and The   Sun Bus continue to   advance...

CSTL : 21.38 (+0.85%)
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus

Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved risk stratification and influences risk-aligned surveillance decisions in clinical practice, with one study...

CSTL : 21.38 (+0.85%)
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS

Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk...

CSTL : 21.38 (+0.85%)
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026

FRIENDSWOOD, Texas , April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will...

CSTL : 21.38 (+0.85%)

Business Summary

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 22.73
2nd Resistance Point 22.33
1st Resistance Point 21.85
Last Price 21.38
1st Support Level 20.98
2nd Support Level 20.58
3rd Support Level 20.10

See More

52-Week High 44.28
Fibonacci 61.8% 32.94
Fibonacci 50% 29.43
Fibonacci 38.2% 25.93
Last Price 21.38
52-Week Low 14.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.